Non alcoholic fatty liver disease: pathogenesis, role of (TNF-α, IL-6) in hepatic inflammation and future potential nutraceutical treatment
Faheem, S., Saeed, N., El-naga, R., Azab, S. (2019). Non alcoholic fatty liver disease: pathogenesis, role of (TNF-α, IL-6) in hepatic inflammation and future potential nutraceutical treatment. EKB Journal Management System, 3(2), 154-169. doi: 10.21608/aps.2019.17201.1012
Safaa Faheem; Noha Saeed; Reem El-naga; Samar Azab. "Non alcoholic fatty liver disease: pathogenesis, role of (TNF-α, IL-6) in hepatic inflammation and future potential nutraceutical treatment". EKB Journal Management System, 3, 2, 2019, 154-169. doi: 10.21608/aps.2019.17201.1012
Faheem, S., Saeed, N., El-naga, R., Azab, S. (2019). 'Non alcoholic fatty liver disease: pathogenesis, role of (TNF-α, IL-6) in hepatic inflammation and future potential nutraceutical treatment', EKB Journal Management System, 3(2), pp. 154-169. doi: 10.21608/aps.2019.17201.1012
Faheem, S., Saeed, N., El-naga, R., Azab, S. Non alcoholic fatty liver disease: pathogenesis, role of (TNF-α, IL-6) in hepatic inflammation and future potential nutraceutical treatment. EKB Journal Management System, 2019; 3(2): 154-169. doi: 10.21608/aps.2019.17201.1012

Non alcoholic fatty liver disease: pathogenesis, role of (TNF-α, IL-6) in hepatic inflammation and future potential nutraceutical treatment

Archives of Pharmaceutical Sciences Ain Shams University
Article 3, Volume 3, Issue 2 - Serial Number 6, June 2019, Page 154-169  XML PDF (1.04 MB)
Document Type: Review Article
DOI: 10.21608/aps.2019.17201.1012
View on SCiNiTO View on SCiNiTO
Authors
Safaa Faheem email 1; Noha Saeed2; Reem El-naga3; Samar Azab3
1Pharmacology and toxicology department , Faculty of pharmacy, Egyptian Russian University
2Pharmacology and Toxicology department, Faculty of pharmacy, Egyptian Russian University
3Pharmacology and Toxicology department, Faculty of pharmacy, Ain Shams university, Cairo, Egypt
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a pathological condition characterized by the accumulation of triglycerides (TGs) in the hepatocytes and has usually been associated with hyperlipidemia, obesity, and insulin resistance. Besides, it is a progressive condition that has become one of the most common liver disorder in developed countries and is usually accompanied by increased cardiovascular and land liver disease mortality. NAFLD is a spectrum of liver disorders, progressing from simple steatosis to non-alcoholic steatohepatitis which is characterized by inflammation and hepatocellular injury then fibrosis which finally results in cirrhosis and even hepatocellular cancer. However, the molecular mechanism contributing to NAFLD progression is not fully understood. Its pathogenesis has usually been recognized by the "double-insult" hypothesis. the "first insult" includes accumulation of TGs in the hepatocyte, followed by a "second insult" where inflammatory mediators convince hepatocellular injury, inflammation, and fibrosis. In NAFLD, insulin resistance initiates the hepatic steatosis by different mechanisms. Furthermore, it was shown that NAFLD is associated with an inhibition of fatty acid oxidation in the mitochondria and an increase in the release of very-low-density lipoproteins. This review discusses the pathophysiology of NAFLD and the role of insulin resistance, obesity and inflammatory markers in the initiation of NAFLD. in addition to the different Therapeutic approaches for NAFLD.
Keywords
Keywords: non-alcoholic fatty liver disease; Insulin Resistance; IL-6; TNF-α; Oxidative Stress; Cranberry nutraceutical
Statistics
Article View: 680
PDF Download: 692